profit from every $100 of sales.
$0$100
Silexion Therapeutics
$0.00+4.88% today
-88.5% in 1 year
1-year low $0.001-year high $0.05
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Silexion Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$11.9 million of profit last year.
SalesProfit
Silexion Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Silexion Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Silexion Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -4 | -5 | -13 | -12 | |
| -4 | -5 | -16 | -12 | |
| -3 | -5 | -16 | -12 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 9 | 5 | 3 | 7 |
| Cash | 8 | 5 | 1 | 6 |
| Total debt | 0 | 0 | 4 | 2 |
| Total liabilities | 16 | 17 | 7 | 5 |
| -11 | -15 | -4 | 3 | |
| – | – | – | – | |
| – | – | -2,596.9% | -202.6% | |
| 30.1% | 31.9% | 412.2% | -457.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -3 | -5 | -8 | -11 | |
| 0 | 0 | 0 | 0 | |
| -3 | -5 | -8 | -11 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 6 | 0 |
Valuation
- –
- –
- –
- 0.6×
- 0.0×
- –
- 0.4×
- -128,690.3%
- -725.7%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -250.7%
- -720.2%
- -387.8%
- -165.1%
- -261.0%
- –
Growth
- –
- –
- −28.6%
- –
- −46.7%
Financial health
- 0.5×
- 0.18
- 6.5%
- -1,292.4×
- 2.41
- 2.41
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 894
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 18, 2026 | -0.85 | -1.29 | +34.1% |
| Mar 17, 2026 | -2.39 | -1.12 | −112.9% |
| Nov 12, 2025 | -2.88 | -3.40 | +15.3% |
| Aug 12, 2025 | -4.32 | -3.15 | −37.1% |
| May 13, 2025 | -0.26 | -3.30 | +92.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
70Pass
Philip Fisher
41No pass
Peter Lynch
57No pass
Joel Greenblatt
100Pass
Charlie Munger
37No pass
Terry Smith
37No pass
Questions about Silexion Therapeutics
Is Silexion Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Silexion Therapeutics AI analysis
What does Silexion Therapeutics do?
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. It is in Biotechnology.
Does Silexion Therapeutics pay a dividend?
No. Silexion Therapeutics does not pay a dividend at the moment.
How has Silexion Therapeutics stock done over the past year?
Down 88.5% over the past twelve months, to $0.00. It traded between $0.00 and $0.05 and is 91.4% below its high.
Who are Silexion Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Silexion Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.